Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
7
Thermostable Live Attenuated Influenza Vaccine for Nasal Delivery
Award last edited on: 3/13/2019
Sponsored Program
SBIR
Awarding Agency
NIH : CDC
Total Award Amount
$1,099,938
Award Phase
2
Solicitation Topic Code
ODCDC
Principal Investigator
Victor Bronshtein
Company Information
Universal Stabilization Technologies Inc
(
AKA
: UST)
4050 Sorrento Valley Boulevard Suite L
San Diego, CA 92121
(858) 625-2890
info@vitrilife.com
www.vitrilife.com
Location:
Single
Congr. District:
52
County:
San Diego
Phase I
Contract Number:
N/A
Start Date:
00/00/00
Completed:
00/00/00
Phase I year
2016
Phase I Amount
$100,000
No abstract available.
Phase II
Contract Number:
200-2017-95855
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
2017
Phase II Amount
$999,938
Problems exist with current influenza vaccines because of the need for refrigeration virus shedding professionals required for injection or liquid nasal administration and slow egg based production methods which are ineffective for pandemic situations This Phase II project aims to Optimize drying thermostabilization of two live attenuated influenza vaccines LAIV via UST patented Preservation by Vaporization technology The currently utilized BioDiem H N LAIV will be tested against new M SR vaccine produced by FluGen in a cell based system modified to eliminate M expression less likely to replicate and shed Once dried vaccine powders will be micronized and filled into nasal delivery devices Ferrets will be vaccinated via nasal powders Safety and immunogenicity will be assessed then homologous and heterologous influenza challenge will be performed to assess nasal wash virus titer mucosal antibody responses infection rate virus load and duration of shedding Expected outcome is appropriate response to challenge with both vaccines PBV thermostabilization micronization will decrease need for refrigeration allow nasal powder delivery which improves dose variability and eliminates need for professional administration The new M SR vaccine could allow more effective immunization without shedding and possibility of production more suited to needs of government during pandemic situations
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.